April/May #187 : Treatment: Fulyzaq Approved for Diarrhea Relief - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Recovering Your Life

Navigating Treatment as Prevention

From the Editor

High Hopes

Feedback

Letters-April/May 2013

The POZ Q+A

Positive Support

POZ Planet

Return to Sender

Old-School Kicks

My Bloody Valentine

Talk of the Town

Safe Sex 3.0

Bar None

Coming Attractions

Voices

What Would You Do?

Care and Treatment

The Heart of Cardiovascular Risks

E-Reminders Help Patient Outcomes

HIV Docs Slow on Early Treatment

TasP in the Real World

An Almost Normal Life Expectancy?

Research Notes

Prevention: Spinning Beyond Latex and Gels

Treatment: Fulyzaq Approved for Diarrhea Relief

Cure: Embryo Survival Gene to Control HIV

Concerns: HIV-Positive Smokers Lose More Years

POZ Survey Says

Facing Discrimination

POZ Heroes

Not Lost in Translation

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

April / May 2013

Treatment: Fulyzaq Approved for Diarrhea Relief

by Benjamin Ryan

The U.S. Food and Drug Administration (FDA) has approved Fulyzaq (crofelemer), the first drug to relieve symptoms of the diarrhea that is a side effect of antiretrovirals (ARVs). Meant for people with HIV who are on ARVs and whose diarrhea is not caused by a virus, bacteria or parasite, the medication treats watery diarrhea resulting from electrolyte secretion and water in the gastrointestinal tract. The clinical trial that proved the safety and efficacy of Fulyzaq involved 374 HIV-positive participants on stable ARVs who had a history of diarrhea and experienced a median of 2.5 watery bowel movements each day. Among those who took the drug twice a day, 17.6 percent experienced two or fewer watery bowel movements each week while 8 percent of those taking a placebo reached this clinical benchmark. Common side effects included upper respiratory tract infection, bronchitis, cough, flatulence and increased levels of the liver enzyme bilirubin (which can cause jaundice).

Search: HIV, Fulyzaq, FDA, diarrhea, ARVs side effects

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    fokisi
    Long Beach
    California


    july8th69
    brooklyn
    New York


    TaintedloveDC
    Washington
    DC


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.